Cargando…
Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer
BACKGROUND: Sagopilone is the first fully synthetic epothilone in clinical development and has demonstrated promising preclinical activity. This phase I/II, prospective, open-label trial investigated the efficacy and safety of sagopilone plus carboplatin in patients with recurrent platinum-sensitive...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3251849/ https://www.ncbi.nlm.nih.gov/pubmed/22108514 http://dx.doi.org/10.1038/bjc.2011.499 |
_version_ | 1782220568725028864 |
---|---|
author | McMeekin, S Patel, R Verschraegen, C Celano, P Burke, J Plaxe, S Ghatage, P Giurescu, M Stredder, C Wang, Y Schmelter, T |
author_facet | McMeekin, S Patel, R Verschraegen, C Celano, P Burke, J Plaxe, S Ghatage, P Giurescu, M Stredder, C Wang, Y Schmelter, T |
author_sort | McMeekin, S |
collection | PubMed |
description | BACKGROUND: Sagopilone is the first fully synthetic epothilone in clinical development and has demonstrated promising preclinical activity. This phase I/II, prospective, open-label trial investigated the efficacy and safety of sagopilone plus carboplatin in patients with recurrent platinum-sensitive ovarian cancer (OC). METHODS: In phase I (dose-escalation stage), patients with OC recurring at least 6 months after platinum-containing chemotherapy received 3-h infusions of sagopilone (initial dose of 12 mg m(−2)) followed by carboplatin every 3 weeks, for 2–6 treatment courses. Patients enrolled in phase II received 3-h infusions of 16 mg m(−2) sagopilone. Efficacy was assessed using modified Response Evaluation Criteria in Solid Tumors (modRECIST) and Gynecologic Cancer InterGroup CA125 criteria. The safety and tolerability of sagopilone were also evaluated. RESULTS: In all, 45 patients received sagopilone at 12 mg m(−2) or 16 mg m(−2). There were 29 confirmed tumour responses (21 modRECIST and 8 CA125) across both treatment groups, indicating that the primary objective of the study was reached. The main adverse events (AEs) reported were peripheral neuropathy (75.6%), fatigue (71.1%) and nausea (64.4%). Grade ⩾3 AEs occurred in 35 patients (77.8%). No deaths related to the study drug were reported. CONCLUSION: Sagopilone in combination with carboplatin was effective and toxicities were manageable in patients with recurrent platinum-sensitive OC. |
format | Online Article Text |
id | pubmed-3251849 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-32518492013-01-03 Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer McMeekin, S Patel, R Verschraegen, C Celano, P Burke, J Plaxe, S Ghatage, P Giurescu, M Stredder, C Wang, Y Schmelter, T Br J Cancer Clinical Study BACKGROUND: Sagopilone is the first fully synthetic epothilone in clinical development and has demonstrated promising preclinical activity. This phase I/II, prospective, open-label trial investigated the efficacy and safety of sagopilone plus carboplatin in patients with recurrent platinum-sensitive ovarian cancer (OC). METHODS: In phase I (dose-escalation stage), patients with OC recurring at least 6 months after platinum-containing chemotherapy received 3-h infusions of sagopilone (initial dose of 12 mg m(−2)) followed by carboplatin every 3 weeks, for 2–6 treatment courses. Patients enrolled in phase II received 3-h infusions of 16 mg m(−2) sagopilone. Efficacy was assessed using modified Response Evaluation Criteria in Solid Tumors (modRECIST) and Gynecologic Cancer InterGroup CA125 criteria. The safety and tolerability of sagopilone were also evaluated. RESULTS: In all, 45 patients received sagopilone at 12 mg m(−2) or 16 mg m(−2). There were 29 confirmed tumour responses (21 modRECIST and 8 CA125) across both treatment groups, indicating that the primary objective of the study was reached. The main adverse events (AEs) reported were peripheral neuropathy (75.6%), fatigue (71.1%) and nausea (64.4%). Grade ⩾3 AEs occurred in 35 patients (77.8%). No deaths related to the study drug were reported. CONCLUSION: Sagopilone in combination with carboplatin was effective and toxicities were manageable in patients with recurrent platinum-sensitive OC. Nature Publishing Group 2012-01-03 2011-11-22 /pmc/articles/PMC3251849/ /pubmed/22108514 http://dx.doi.org/10.1038/bjc.2011.499 Text en Copyright © 2012 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Clinical Study McMeekin, S Patel, R Verschraegen, C Celano, P Burke, J Plaxe, S Ghatage, P Giurescu, M Stredder, C Wang, Y Schmelter, T Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer |
title | Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer |
title_full | Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer |
title_fullStr | Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer |
title_full_unstemmed | Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer |
title_short | Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer |
title_sort | phase i/ii study of sagopilone (zk-epo) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3251849/ https://www.ncbi.nlm.nih.gov/pubmed/22108514 http://dx.doi.org/10.1038/bjc.2011.499 |
work_keys_str_mv | AT mcmeekins phaseiiistudyofsagopilonezkepopluscarboplatininwomenwithrecurrentplatinumsensitiveovariancancer AT patelr phaseiiistudyofsagopilonezkepopluscarboplatininwomenwithrecurrentplatinumsensitiveovariancancer AT verschraegenc phaseiiistudyofsagopilonezkepopluscarboplatininwomenwithrecurrentplatinumsensitiveovariancancer AT celanop phaseiiistudyofsagopilonezkepopluscarboplatininwomenwithrecurrentplatinumsensitiveovariancancer AT burkej phaseiiistudyofsagopilonezkepopluscarboplatininwomenwithrecurrentplatinumsensitiveovariancancer AT plaxes phaseiiistudyofsagopilonezkepopluscarboplatininwomenwithrecurrentplatinumsensitiveovariancancer AT ghatagep phaseiiistudyofsagopilonezkepopluscarboplatininwomenwithrecurrentplatinumsensitiveovariancancer AT giurescum phaseiiistudyofsagopilonezkepopluscarboplatininwomenwithrecurrentplatinumsensitiveovariancancer AT stredderc phaseiiistudyofsagopilonezkepopluscarboplatininwomenwithrecurrentplatinumsensitiveovariancancer AT wangy phaseiiistudyofsagopilonezkepopluscarboplatininwomenwithrecurrentplatinumsensitiveovariancancer AT schmeltert phaseiiistudyofsagopilonezkepopluscarboplatininwomenwithrecurrentplatinumsensitiveovariancancer |